Abstracts tagged "meta-analysis"

Abstract Number: 1323 • 2019 ACR/ARP Annual Meeting
Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma
Lilian SOLE¹, Arthur Beck ¹, Thomas Barnetche ² and Pascale Vergne-Salle ³, ¹CHU de Limoges, LIMOGES, France, ²CHU, Toulouse, France, ³CHU limoges, Limoges, France
Background/Purpose: While there is growing evidences for the efficacy of platelet-rich plasma (PRP), there is still no standardized composition. There are 3 major types of…
Abstract Number: 2180 • 2019 ACR/ARP Annual Meeting
High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis
Charles Hummer ¹, Felix Angst ², Emil Schemitsch ³, Craig Whittington ⁴, Colleen Manitt ⁵ and Wilson Ngai⁶, ¹Premier Orthopaedics and Sports Medicine, Media, PA, ²Research Department, Rehabilitation Clinic (‘RehaClinic’), Bad Zurzach, Switzerland, ³London Health Sciences Centre, London, Ontario, Canada, ⁴Doctor Evidence, Santa Monica, CA, ⁵International Centre for Professional Development in Health and Medicine, Quebec, Canada, ⁶Sanofi, U.S. Medical Affairs, Bridgewater
Background/Purpose: The 2013 American Academy of Orthopaedic Surgeons (AAOS) clinical practice guideline (CPG) on the treatment of knee OA made a strong recommendation not in…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 222 • 2018 ACR/ARHP Annual Meeting
Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence
Fatima Kudaeva¹, Janet E. Pope² and Mark Speechley³, ¹Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Department of Medicine, University of Western Ontario, London, ON, Canada, ³Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex etiology. Infections are viewed as environmental triggers of RA. Different viral exposures have been…
Abstract Number: 427 • 2018 ACR/ARHP Annual Meeting
One Year Efficacy and Safety of One or Three Injections of Hylan G-F 20 for Knee Osteoarthritis: A Systematic Literature Review and Meta-Analysis
Orazio De Lucia¹, Georgios Filippou², Joerg Jerosch³, Sophie Yoon⁴, Jean-Francois Bitsch⁴, Tobias Sayre⁴ and Wilson Ngai⁵, ¹Division of Clinical Rheumatology, G. Pini Hospital, Milan, Italy, ²Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, ³Department of Orthopedic Surgery, Johanna-Etienne Krankenhaus, Neuss, Germany, ⁴Doctor Evidence, Santa Monica, CA, ⁵Global Medical Affairs, General Medicines and Emerging Markets, Sanofi, Bridgewater, NJ
Background/Purpose: Hylan G-F 20 is indicated for the treatment of pain in knee osteoarthritis (OA) in patients who failed to respond adequately to conservative nonpharmacologic…
Abstract Number: 537 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
Patompong Ungprasert¹ and Sukit Raksasuk², ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Increased Risk of Incident Chronic Kidney Disease among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Cohort Studies AbstractBackground/Purpose: Patients with rheumatoid arthritis (RA)…
Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Aliza Matusevich², Scott B. Cantor³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Anna-Maria Hoffmann-Vold¹, Toby Maher², Edward Philpot³, Ali Ashrafzadeh⁴, Diwakar Jha⁵, Margarida Alves⁶ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Royal Brompton Hospital, London, United Kingdom, ³IQVIA, Durham, NC, ⁴IQVIA, Los Angeles, CA, ⁵IQVIA, Gurugram, India, ⁶Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…
Abstract Number: 2262 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Sarcoidosis Among Patients with Celiac Disease: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Karn Wijarnpreecha², Panadeekarn Panjawatanan³, Ploypin Lertjitbanjong² and Juan Corral⁴, ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Internal medicine, Bassett medical center, cooperstown, NY, ³Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Internal medicine, Mayo Clinic, Jacksonville, Jacksonville, FL
Increased Risk of Sarcoidosis among Patients with Celiac Disease: A Systematic Review and Meta-Analysis AbstractBackground/Purpose: Several epidemiologic studies have suggested that patients with celiac disease may…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data
Amanda M. Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Mokbel⁴, Cecilia Nalli⁵, Laura Andreoli⁵, Angela Tincani⁶, Yair Molad⁷, Stephen Balevic⁸ and Megan E. B. Clowse¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, ⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Mahdi Gharaibeh¹, Yingxin Xu², Joseph Lee³, Madhura Chitnis² and David Collier⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Evidera, Bethesda, MD, ³videra, Bethesda, MD, ⁴Amgen, Inc, Terni, Italy
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…
Abstract Number: 2127 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors for Sarcoidosis
Stefanie Wade¹ and Mollie Carruthers², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with sarcoidosis refractory to standard treatment are a therapeutic challenge and are often managed by a variety of specialists due to the heterogeneity…
Abstract Number: 2262 • 2017 ACR/ARHP Annual Meeting
Knowledge, Beliefs and Concerns about Osteoporosis – a Qualitative Synthesis
Jude des Bordes¹, Seema Prasad², Gregory Pratt³, Maria Suarez-Almazor¹ and Maria A. Lopez-Olivo¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Gastroenterology Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Educating patients with osteoporosis about bone health could increase their knowledge and self-efficacy. These can help them adopt healthy lifestyles to prevent osteoporosis-associated fractures.…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].